Oxybutynin transdermal - Hisamitsu

Drug Profile

Oxybutynin transdermal - Hisamitsu

Alternative Names: HOB-294; Neoxy Tape

Latest Information Update: 31 Mar 2016

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 17 Mar 2016 Hisamitsu and Asahi Kasei agree to discontinue joint sales of NEOXY® Tape 73.5 mg for Overactive bladder in Japan
  • 25 Mar 2013 Registered for Overactive bladder in Japan (Transdermal)
  • 10 Dec 2012 Oxybutynin transdermal licensed to Asahi Kasei Pharma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top